

Docket #: S93-116

Antibodies to Human B7 Integrin: DATK32, FIB504, FIB27

The invention consists of the ability to treat inflammatory and autoimmune disorders, particularly but not exclusively those involving mucosal sites such as in the chronic inflammatory bowel disease, by blocking or altering 4B7 interactions with vascular and extracellular matrix ligands, thus altering lymphocyte and leukocyte recruitment from the blood into mucosal sites, and modulating local inflammatory responses.

DATK-32: ATCC Number: HB-294:

Rat IgG2a monoclonal antibody specific for the mouse a4B7 integrin heterodimer. Induces a4B7-dependent lymphocyte aggregation, but inhibits other a4B7-mediated lymphocyte adhesion events including binding to MAdCAM-1 and a4B7-dependent VAM-1 and fibronectin binding. Useful in flow cytometry with sensitive second-stage reagents. Ineffective in immunohistology.

FIB504: ATCC Number: HB-293

FIB21: ATCC Number: HB295

Rat IgG2a antibodies to human and mouse B7 integrin chain. FIB504 blocks lymphocyte binding to MAdCAM-1, a4b7 binding to VCAM-1 and fibronectin, and aeB7-dependent binding to intestinal epithelial cells. FIB21 also blocks, albeit less well, and is good for immunofluorescence and histology.

Publications

- J. Immunol., 153:3847-3861, 1994 Andrew, D.P.
- Cell, Vol. 74, 185-195, July 16, 1993.

Innovators

- David Andrew
- Eugene Butcher

Licensing Contact

Michael Bellas

Licensing Associate

[Email](#)